Prime Capital Investment Advisors’s Pacific Biosciences PACB Stock Holding History

Prime Capital Investment Advisors’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$33.5K	Sell	19,923 -356	-2%	-$518	﹤0.01%	1071
2026 Q1	$26.8K	Sell	20,279 -1,694	-8%	-$3.03K	﹤0.01%	1031
2025 Q4	$41.1K	Buy	21,973 +166	+0.8%	+$319	﹤0.01%	1005
2025 Q3	$27.9K	Sell	21,807 -2,317	-10%	-$3.14K	﹤0.01%	991
2025 Q2	$29.9K	Sell	24,124 -11,583	-32%	-$13.4K	﹤0.01%	938
2025 Q1	$42.1K	Buy	35,707 +370	+1%	+$568	﹤0.01%	1030
2024 Q4	$64.7K	Buy	+35,337	New	+$69K	﹤0.01%	908
2023 Q3	–	Sell	-19,286	Closed	-$257K	–	789
2023 Q2	$257K	Sell	19,286 -1,747	-8%	-$21.2K	0.01%	648
2023 Q1	$244K	Buy	+21,033	New	+$209K	0.01%	471

Other funds holding PACB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return

Prime Capital Investment Advisors's PACB Position: Q2 2026 in Review

Prime Capital Investment Advisors reduced its Pacific Biosciences (PACB) stake by 1.8% in Q2 2026, selling an estimated $518 and leaving 19,923 shares worth $33.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1071.

Prime Capital Investment Advisors first reported a position in PACB in Q1 2023 and has held it in 9 quarters since. The position peaked at $257K in Q2 2023. 152 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

Prime Capital Investment Advisors held 19,923 shares of Pacific Biosciences worth $33.5K as of Q2 2026.
Prime Capital Investment Advisors sold 356 Pacific Biosciences shares in Q2 2026, an estimated $518.
Pacific Biosciences made up ﹤0.01% of Prime Capital Investment Advisors's portfolio in Q2 2026, its #1071 holding.
Prime Capital Investment Advisors first reported a position in Pacific Biosciences in Q1 2023 and has held it in 9 quarters since.
Prime Capital Investment Advisors's Pacific Biosciences position peaked at $257K in Q2 2023.
152 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Prime Capital Investment Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.